At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 12 enrolled
Drug / intervention
Letrozole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pilot of Letrozole for Uterine Myomas
In Brief
A Phase 4 clinical trial evaluating Letrozole and Placebo for Leiomyoma and Uterine Fibroids. Completed, enrolled 12 participants across 1 site.
Detailed Summary
PLUM evaluates the drug letrozole as a treatment for uterine fibroids. This study is a randomized, blinded, placebo-controlled trial of oral letrozole among premenopausal women with symptomatic uterine fibroids. Participants will be randomly assigned in a 1:1 ratio to either oral letrozole 2.5mg/day for 6 months (Group A) or intermittent dosing with letrozole 2.5mg/day and an identical placebo capsule (Group B).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeiomyoma, Uterine Fibroids
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartJul 2015
Primary CompletionDec 2017
TodayJul 2026
First PostedJun 12, 2015
Enrollment StartJul 1, 2015
Primary CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 11.1 years ago
Interventions
Letrozoledrug
Placeboother